During the past decade, Waring Vision Institute conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Waring Vision Institute" #1 collaborator was "Johnson & Johnson Surgical Vision, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Waring Vision Institute" are "Cataract" (1 trials) and "Presbyopia" (1 trials). Many other conditions were trialed in "Waring Vision Institute" in a lesser frequency.

Most popular intervention types in "Waring Vision Institute" are "Device" (1 trials), "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Intraocular lens" (1 trials), "Pilocarpine HCl Ophthalmic Solution" (1 trials) and "Vehicle" (1 trials). Other intervention names were less common.

The vast majority of trials in "Waring Vision Institute" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Waring Vision Institute". 1 are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Waring Vision Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Waring Vision Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".